Anzeige
Mehr »
Mittwoch, 11.02.2026 - Börsentäglich über 12.000 News
Breaking News: Pacifica meldet neue hochgradige Entdeckung und genau deshalb kann der Markt das nicht ignorieren
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
ACCESS Newswire
526 Leser
Artikel bewerten:
(2)

OneMedNet Expands Leadership Team with Addition of Technology Leader, Steven Chartier

Addition of Steven highlights OneMedNet's Growth Trajectory and adds to our Bench of Industry Leading Talent in Life Sciences Domain and Technology

MINNEAPOLIS, MN / ACCESSWIRE / October 3, 2023 / OneMedNet Corporation ("OneMedNet" or the "Company"), the leading curator of regulatory-grade Imaging Real Word Data, through its proven OneMedNet iRWD solution, today announced that it has expanded its executive leadership with the addition of Steven Chartier, as Director Product Management, Head of Data, effective today. The addition of Steven highlights OneMedNet's growth trajectory and add to the company's industry-leading talent.

Mr. Chartier brings more than 30 years of proven experience delivering technology solutions and leading transformative data technology experience in the healthcare space across the full clinical trial spectrum from protocol development to post market surveillance to his role as Director Product Management, Head of Data. At OneMedNet, Mr. Chartier will be responsible for the product direction of OneMedNet's indexing platform and data solutions and will report directly to President, Aaron Green. He has led technology and product initiatives to create full clinical trial platforms providing trial oversight, site management, subject randomization, medical imaging reads, data streaming, clinical risk mitigation, and drug efficacy.

Mr. Chartier joins from Calyx, an Enterprise Software as a Service ("SaaS") provider where he was Senior Director of Technology and led the development of data and analytics strategies and unified 1,000's of heterogeneous data silos into one data platform to optimize delivery of Medical Imaging ("MI") services. Previously, he was Director of Technology at Parexel, one of the world's leading global clinical research organizations, where he served for more than 15 years. At Parexel, he introduced their first data hub and analytics warehouse unifying clinical data from more than 3,000 clinical trials leading a program to improve electronic data capture quality dramatically to enhance Parexel's business futures in risk-based fundamentally monitoring.

"Steven is a great addition to our leadership team," commented Aaron Green, President of OneMedNet. "His extensive experience, as a proven leader delivering technology solutions in data analytics and architecture, data silo unification and mining, and technology team management, will be extremely beneficial to our organization, our partners, and our customers."

"Joining OneMedNet is a once-in-a-lifetime opportunity to transform the curation of Real World Data in a way that is effective, accessible, and sustainable," said Mr. Chartier. "I truly believe that OneMedNet's iRWD solution is pioneering the future of Real World Data curation. I am excited to be part of this amazing journey and contribute to the Company's growth trajectory."

Mr. Chartier holds a Master of Science in Computer Engineering from Boston University and a Bachelor of Science in Electrical Engineering from Cornell University.

About OneMedNet Corporation

Founded in 2009, OneMedNet provides innovative solutions that unlock the significant value contained within the clinical image archives of healthcare providers. Employing its proven OneMedNet iRWD solution, OneMedNet securely de-identifies, searches, and curates a data archive locally, bringing a wealth of internal and third-party research opportunities to providers. By leveraging this extensive federated provider network, together with industry leading technology and in-house clinical expertise, OneMedNet successfully meets the most rigorous RWD Life Science requirements. As previously announced, OneMedNet signed a definitive business combination agreement with Data Knights Acquisition Corp. (Nasdaq:DKDC), a special purpose acquisition company, on April 25, 2022, that will result in a newly combined company to be publicly listed that is expected to close in October 2023. For more information, please visit www.onemednet.com.

Investor Contact:

Shannon Devine
MZ Group North America
203-741-8811
OMN@mzgroup.us

SOURCE: ONEMEDNET CORP.

View source version on accesswire.com:
https://www.accesswire.com/789651/onemednet-expands-leadership-team-with-addition-of-technology-leader-steven-chartier

© 2023 ACCESS Newswire
Favoritenwechsel
Das Börsenjahr 2026 ist für viele Anleger ernüchternd gestartet. Tech-Werte straucheln, der Nasdaq 100 tritt auf der Stelle und ausgerechnet alte Favoriten wie Microsoft und SAP rutschen zweistellig ab. KI ist plötzlich kein Rückenwind mehr, sondern ein Belastungsfaktor, weil Investoren beginnen, die finanzielle Nachhaltigkeit zu hinterfragen.

Gleichzeitig vollzieht sich an der Wall Street ein lautloser Favoritenwechsel. Während viele auf Wachstum setzen, feiern Value-Titel mit verlässlichen Cashflows ihr Comeback: Telekommunikation, Industrie, Energie, Pharma – die „Cashmaschinen“ der Realwirtschaft verdrängen hoch bewertete Hoffnungsträger.

In unserem aktuellen Spezialreport stellen wir fünf Aktien vor, die genau in dieses neue Marktbild passen: solide, günstig bewertet und mit attraktiver Dividende. Werte, die nicht nur laufende Erträge liefern, sondern auch bei Marktkorrekturen Sicherheit bieten.

Jetzt den kostenlosen Report sichern – bevor der Value-Zug 2026 endgültig abfährt!

Dieses exklusive PDF ist nur für kurze Zeit gratis verfügbar.
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.